PRPO Precipio, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.00
P/S
1.63
EV/EBITDA
46.55
DCF Value
$-262.02
FCF Yield
1.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
43.3%
Operating Margin
-6.8%
Net Margin
-3.5%
ROE
-6.7%
ROA
-4.4%
ROIC
-10.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $6.3M | $-1.4M | $— |
| Q4 null | $8.0M | $526.0K | $— |
| FY null | $24.0M | $-363.0K | $— |
| Q3 null | $6.2M | $-79.0K | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
1.38
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.